Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and ...
Organogenesis provides update on Phase 3 trial of ReNu in knee osteoarthritis
Organogenesis (ORGO) announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a ...
Organogenesis (ORGO) Q3 2024 Earnings Call Transcript
ORGO earnings call for the period ending September 30, 2024. Organogenesis ( ORGO -1.43%) Q3 2024 Earnings Call Nov 12, 2024, ...
Organogenesis Holdings Inc.: Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...
Organogenesis Holdings And 2 Other US Penny Stocks To Watch
As the U.S. stock market navigates the uncertainty surrounding the presidential election and upcoming Federal Reserve interest rate decisions, investors are keeping a close eye on various sectors for ...
BioSpace24d
Organogenesis Shares ReNu® Program Update
Organogenesis recently completed enrollment in the second Phase 3 multi-center RCT evaluating the safety and efficacy of ReNu with 594 patients, significantly outperforming enrollment expectations.
ETF Daily News4d
Organogenesis (ORGO) Set to Announce Quarterly Earnings on Tuesday
Organogenesis Stock Performance Organogenesis stock opened at $3.28 on Friday. The company’s 50-day moving average price is $2.90 and its 200-day moving average price is $2.78. The company has a ...